Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 12:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 141 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Normal Hepatic Function Clear all

Conditions: Healthy, Hepatic Insufficiency
Interventions: Canagliflozin; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Orlando, Florida • Knoxville, Tennessee

Conditions: Hepatic Impairment, Hepatic Function
Interventions: Lenvatinib; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 5
States / cities: Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more

Conditions: Breast Cancer
Interventions: trastuzumab emtansine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Fort Myers, Florida • Detroit, Michigan • Portland, Oregon + 1 more

Conditions: Normal Non-fluency
Interventions: Olanzapine; Drug
Lead sponsor: Michael Rickels; Other
Eligibility: 18 Years to 40 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: Nilotinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Hepatic Impairment, Healthy
Interventions: Palovarotene; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Conditions: Pharmacokinetics, Hepatic Impairment
Interventions: Midomafetamine HCl; Drug
Lead sponsor: Resilient Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Severe Hepatic Impairment, Normal Hepatic Function
Interventions: Vorasidenib 20mg; Drug
Lead sponsor: Institut de Recherches Internationales Servier (I.R.I.S.); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 3
States / cities: Chandler, Arizona • Orlando, Florida • San Antonio, Texas

Conditions: Hepatic Impairment
Interventions: KD025; Drug
Lead sponsor: Kadmon, a Sanofi Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 5
States / cities: Rialto, California • Miami, Florida • Orlando, Florida + 1 more

Conditions: Hepatic Insufficiency
Interventions: BI 1584862; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Chandler, Arizona • Orlando, Florida • San Antonio, Texas

Conditions: Hepatic Impairment
Interventions: Iptacopan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hepatic Impairment
Interventions: Vadadustat; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Saint Paul, Minnesota • San Antonio, Texas

Conditions: Hepatic Impairment, Healthy Participants
Interventions: Linzagolix; Drug
Lead sponsor: ObsEva SA; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 2
States / cities: Hialeah, Florida • Orlando, Florida

Conditions: Moderate Hepatic Impairment
Interventions: Mitapivat; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 3
States / cities: Tustin, California • Miami, Florida • Orlando, Florida

Conditions: Rheumatoid Arthritis
Interventions: Filgotinib; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Miami, Florida • San Antonio, Texas

Conditions: Advanced Solid Tumors, Hematologic Malignancies
Interventions: Pralatrexate Injection; Drug
Lead sponsor: Acrotech Biopharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Cerritos, California • Chicago, Illinois • Detroit, Michigan + 1 more

Conditions: Oncology
Interventions: Entospletinib; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more

Conditions: Healthy Participants, Hepatic Impairment
Interventions: Casdatifan; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hepatic Impairment, Healthy Participants
Interventions: PF-06651600 30 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Hepatic Impairment
Interventions: Emraclidine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Conditions: Hepatic Insufficiency, Neoplasms
Interventions: Onureg; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Iowa City, Iowa • Detroit, Michigan • Cleveland, Ohio + 1 more

Conditions: Obesity, Hepatic Insufficiency
Interventions: CP-945,598; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Moderate Liver Impairment, Severe Liver Impairment
Interventions: BMS-986036; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Conditions: Severe Hepatic Impairment
Interventions: Dacomitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida

Search by objective public record fields.

A Study of Canagliflozin in Study Participants With Various Degrees of Impaired Hepatic (Liver) Function

A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)

A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

Effect of Short Term Atypical Antipsychotic Administration Compared to Placebo on Hepatic Insulin Extraction

Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function

A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose

MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function

Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants

KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment

A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems

Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.

A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function

Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic Function

A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function

Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic Function

Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment

Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function

Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine

A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies

Study Examining The Effect Of Hepatic Impairment On Safety, Toleration And How The Body Processes An Experimental Drug

A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment

Evaluate Severe Hepatic Impairment on Dacomitinib PK